temozolomide has been researched along with Experimental Neoplasms in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enhanced drug localization at the tumor sites with minimal toxicity was demonstrated using dendrimer-conjugated temozolomide for treating experimental lymphoma, developed as a solid tumor." | 8.02 | Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy. ( Hira, SK; Manna, PP; Rej, A; RoyMahapatra, D; Sk, UH, 2021) |
| "The frequent recurrence of glioblastoma multiforme (GBM) after standard treatment with temozolomide (TMZ) is a crucial issue to be solved in the clinical field." | 7.80 | YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. ( Akiyama, Y; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Oshita, C; Sugino, T; Yamaguchi, K, 2014) |
| "Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM)." | 7.79 | Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. ( Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S, 2013) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma." | 7.73 | Potentiation of antiglioma effect with combined temozolomide and interferon-beta. ( Hong, YK; Joe, YA; Kim, TG; Park, JA, 2006) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | 5.43 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| " It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected." | 5.32 | Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. ( Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003) |
| "Enhanced drug localization at the tumor sites with minimal toxicity was demonstrated using dendrimer-conjugated temozolomide for treating experimental lymphoma, developed as a solid tumor." | 4.02 | Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy. ( Hira, SK; Manna, PP; Rej, A; RoyMahapatra, D; Sk, UH, 2021) |
| " The chemotherapy drug temozolomide (TMZ), embedded in nanobubbles (NBs) and combined with persistent luminescent nanoparticles (PLNs), has been used to treat glioblastoma (GBM) effectively through image tracking." | 4.02 | Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites. ( Chan, MH; Cheng, CL; Feng, SJ; Hsiao, M; Liu, RS, 2021) |
| "The frequent recurrence of glioblastoma multiforme (GBM) after standard treatment with temozolomide (TMZ) is a crucial issue to be solved in the clinical field." | 3.80 | YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. ( Akiyama, Y; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Oshita, C; Sugino, T; Yamaguchi, K, 2014) |
| "Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM)." | 3.79 | Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. ( Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S, 2013) |
| "The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 3.76 | Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K, 2010) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma." | 3.73 | Potentiation of antiglioma effect with combined temozolomide and interferon-beta. ( Hong, YK; Joe, YA; Kim, TG; Park, JA, 2006) |
| " BCNU, fotemustin, and temozolomide dramatically increased the time of survival of the Hs683 oligodendroglioma-bearing mice, whereas temozolomide only induced a weak but nevertheless statistically significant increase in the U373 glioma-bearing mice." | 3.71 | Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. ( Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F, 2002) |
| "Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity." | 1.46 | Zika virus has oncolytic activity against glioblastoma stem cells. ( Chai, JN; Chheda, MG; Diamond, MS; Fernandez, E; Gorman, MJ; Hubert, CG; McKenzie, LD; Prager, BC; Rich, JN; Richner, JM; Shan, C; Shi, PY; Tycksen, E; Wang, X; Zhang, R; Zhu, Z, 2017) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | 1.43 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| "Nasopharyngeal carcinoma is a rare but highly invasive cancer." | 1.39 | PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. ( Chen, H; Cheung, F; Chow, JP; Li Lung, M; Man, WY; Mao, M; Nicholls, J; Poon, RY; Tsao, SW, 2013) |
| " It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential of both the agents." | 1.38 | The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. ( Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012) |
| " We develop a maximum likelihood method based on the expectation/conditional maximization (ECM) algorithm to estimate the dose-response relationship while accounting for the informative censoring and the constraints of model parameters." | 1.33 | Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. ( Fang, HB; Houghton, PJ; Tan, M; Tian, GL, 2005) |
| " It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected." | 1.32 | Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. ( Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003) |
| " For example, Abdelbasit and Plackett proposed an optimal design assuming that the dose-response relationship follows some specified linear models." | 1.32 | Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. ( Fang, HB; Houghton, PJ; Tan, M; Tian, GL, 2003) |
| "Temozolomide was administered p." | 1.31 | Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. ( Brent, TP; Friedman, HS; Houghton, PJ; Kirstein, MN; Middlemas, DS; Poquette, C; Stewart, CF, 2000) |
| " Statistical analyses of pharmacokinetic and pharmacodynamic end points in the control and TNP-470 treatment groups were completed by nonparametric tests." | 1.31 | Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. ( Chu, J; Gallo, JM; Li, S; Ma, J; Pulfer, S; Reed, K, 2001) |
| " The half-life of the drug in the tumors was approximately 60 min." | 1.29 | Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. ( Artemov, D; Bhujwalla, ZM; Glickson, JD; Griffiths, JR; Judson, IR; Leach, MO; Maxwell, RJ, 1995) |
| " The half-life of CCRG 81045 at 37 degrees C in 0." | 1.27 | Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ( Baig, G; Chubb, D; Gibson, NW; Goddard, C; Hickman, JA; Langdon, SP; Slack, JA; Stevens, MF; Stone, R; Vickers, L, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 12 (27.91) | 29.6817 |
| 2010's | 20 (46.51) | 24.3611 |
| 2020's | 6 (13.95) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, GD | 1 |
| Gong, J | 1 |
| Gandhi, VB | 1 |
| Liu, X | 2 |
| Shi, Y | 2 |
| Johnson, EF | 2 |
| Donawho, CK | 2 |
| Ellis, PA | 2 |
| Bouska, JJ | 1 |
| Osterling, DJ | 1 |
| Olson, AM | 1 |
| Park, C | 1 |
| Luo, Y | 1 |
| Shoemaker, A | 1 |
| Giranda, VL | 1 |
| Penning, TD | 2 |
| Xiang, W | 1 |
| Quadery, TM | 1 |
| Hamel, E | 1 |
| Luckett-Chastain, LR | 1 |
| Ihnat, MA | 1 |
| Mooberry, SL | 1 |
| Gangjee, A | 1 |
| Walunj, D | 1 |
| Thankarajan, E | 1 |
| Prasad, C | 1 |
| Tuchinsky, H | 1 |
| Baldan, S | 1 |
| Sherman, MY | 1 |
| Patsenker, L | 1 |
| Gellerman, G | 1 |
| Lu, Y | 1 |
| Feng, Y | 1 |
| Li, Z | 1 |
| Li, J | 2 |
| Zhang, H | 1 |
| Hu, X | 1 |
| Jiang, W | 1 |
| Shi, T | 1 |
| Wang, Z | 1 |
| He, Y | 1 |
| Yang, C | 1 |
| Wang, Y | 2 |
| Sacher, JR | 1 |
| Sims, MM | 1 |
| Pfeffer, LM | 1 |
| Miller, DD | 1 |
| Sk, UH | 1 |
| Hira, SK | 1 |
| Rej, A | 1 |
| RoyMahapatra, D | 1 |
| Manna, PP | 1 |
| Tsai, CK | 1 |
| Huang, LC | 1 |
| Wu, YP | 1 |
| Kan, IY | 1 |
| Hueng, DY | 1 |
| Cheng, CL | 1 |
| Chan, MH | 1 |
| Feng, SJ | 1 |
| Hsiao, M | 1 |
| Liu, RS | 1 |
| Huang, N | 1 |
| Li, H | 1 |
| Liu, S | 1 |
| Chen, X | 1 |
| Yu, S | 1 |
| Wu, N | 1 |
| Bian, XW | 1 |
| Shen, HY | 1 |
| Li, C | 1 |
| Xiao, L | 1 |
| Peng, P | 1 |
| Wei, W | 1 |
| Long, C | 1 |
| Zhu, Z | 1 |
| Gorman, MJ | 1 |
| McKenzie, LD | 1 |
| Chai, JN | 1 |
| Hubert, CG | 1 |
| Prager, BC | 1 |
| Fernandez, E | 1 |
| Richner, JM | 1 |
| Zhang, R | 1 |
| Shan, C | 1 |
| Tycksen, E | 1 |
| Wang, X | 1 |
| Shi, PY | 1 |
| Diamond, MS | 1 |
| Rich, JN | 1 |
| Chheda, MG | 1 |
| Martínez-Aranda, A | 1 |
| Hernández, V | 1 |
| Picón, C | 1 |
| Modolell, I | 1 |
| Sierra, A | 1 |
| Viel, T | 1 |
| Schelhaas, S | 1 |
| Wagner, S | 1 |
| Wachsmuth, L | 1 |
| Schwegmann, K | 1 |
| Kuhlmann, M | 1 |
| Faber, C | 1 |
| Kopka, K | 1 |
| Schäfers, M | 1 |
| Jacobs, AH | 1 |
| Chow, JP | 1 |
| Man, WY | 1 |
| Mao, M | 1 |
| Chen, H | 1 |
| Cheung, F | 1 |
| Nicholls, J | 1 |
| Tsao, SW | 1 |
| Li Lung, M | 1 |
| Poon, RY | 1 |
| Xiao, Y | 1 |
| Ramiscal, J | 1 |
| Kowanetz, K | 1 |
| Del Nagro, C | 1 |
| Malek, S | 1 |
| Evangelista, M | 1 |
| Blackwood, E | 1 |
| Jackson, PK | 1 |
| O'Brien, T | 1 |
| Stedt, H | 1 |
| Samaranayake, H | 1 |
| Pikkarainen, J | 1 |
| Määttä, AM | 1 |
| Alasaarela, L | 1 |
| Airenne, K | 1 |
| Ylä-Herttuala, S | 1 |
| Ashizawa, T | 2 |
| Akiyama, Y | 2 |
| Miyata, H | 2 |
| Iizuka, A | 2 |
| Komiyama, M | 2 |
| Kume, A | 2 |
| Omiya, M | 2 |
| Sugino, T | 2 |
| Asai, A | 1 |
| Hayashi, N | 2 |
| Mitsuya, K | 2 |
| Nakasu, Y | 2 |
| Yamaguchi, K | 2 |
| Oshita, C | 1 |
| Deibert, CP | 1 |
| Zussman, BM | 1 |
| Engh, JA | 1 |
| McGonigle, S | 1 |
| Chen, Z | 1 |
| Wu, J | 1 |
| Chang, P | 1 |
| Kolber-Simonds, D | 1 |
| Ackermann, K | 1 |
| Twine, NC | 1 |
| Shie, JL | 1 |
| Miu, JT | 1 |
| Huang, KC | 1 |
| Moniz, GA | 1 |
| Nomoto, K | 1 |
| D'Alessandro, G | 1 |
| Grimaldi, A | 1 |
| Chece, G | 1 |
| Porzia, A | 1 |
| Esposito, V | 1 |
| Santoro, A | 1 |
| Salvati, M | 1 |
| Mainiero, F | 1 |
| Ragozzino, D | 1 |
| Di Angelantonio, S | 1 |
| Wulff, H | 1 |
| Catalano, M | 1 |
| Limatola, C | 1 |
| Oplustil O'Connor, L | 1 |
| Rulten, SL | 1 |
| Cranston, AN | 1 |
| Odedra, R | 2 |
| Brown, H | 1 |
| Jaspers, JE | 1 |
| Jones, L | 1 |
| Knights, C | 1 |
| Evers, B | 1 |
| Ting, A | 1 |
| Bradbury, RH | 1 |
| Pajic, M | 1 |
| Rottenberg, S | 1 |
| Jonkers, J | 1 |
| Rudge, D | 1 |
| Martin, NM | 1 |
| Caldecott, KW | 1 |
| Lau, A | 1 |
| O'Connor, MJ | 1 |
| Ohba, S | 1 |
| Hirose, Y | 1 |
| Yoshida, K | 1 |
| Yazaki, T | 1 |
| Kawase, T | 1 |
| Gao, Y | 1 |
| Fotovati, A | 1 |
| Lee, C | 1 |
| Wang, M | 1 |
| Cote, G | 1 |
| Guns, E | 1 |
| Toyota, B | 1 |
| Faury, D | 1 |
| Jabado, N | 1 |
| Dunn, SE | 1 |
| Maag, DX | 1 |
| Palma, JP | 1 |
| Patterson, MJ | 1 |
| Surber, BW | 1 |
| Ready, DB | 1 |
| Soni, NB | 1 |
| Ladror, US | 1 |
| Xu, AJ | 1 |
| Iyer, R | 1 |
| Harlan, JE | 1 |
| Solomon, LR | 1 |
| Shoemaker, AR | 1 |
| Holt, SV | 1 |
| Logié, A | 1 |
| Heier, A | 1 |
| Heaton, SP | 1 |
| Alferez, D | 1 |
| Davies, BR | 1 |
| Wilkinson, RW | 1 |
| Smith, PD | 1 |
| Galbán, S | 1 |
| Lemasson, B | 1 |
| Williams, TM | 1 |
| Li, F | 1 |
| Heist, KA | 1 |
| Johnson, TD | 1 |
| Leopold, JS | 1 |
| Chenevert, TL | 1 |
| Lawrence, TS | 1 |
| Rehemtulla, A | 1 |
| Mikkelsen, T | 1 |
| Holland, EC | 1 |
| Galbán, CJ | 1 |
| Ross, BD | 1 |
| Branle, F | 1 |
| Lefranc, F | 1 |
| Camby, I | 1 |
| Jeuken, J | 1 |
| Geurts-Moespot, A | 1 |
| Sprenger, S | 1 |
| Sweep, F | 1 |
| Kiss, R | 1 |
| Salmon, I | 1 |
| Tan, M | 3 |
| Fang, HB | 3 |
| Tian, GL | 3 |
| Houghton, PJ | 4 |
| Ma, J | 2 |
| Li, S | 2 |
| Reed, K | 2 |
| Guo, P | 1 |
| Gallo, JM | 2 |
| Kokkinakis, DM | 1 |
| Ahmed, MM | 1 |
| Chendil, D | 1 |
| Moschel, RC | 1 |
| Pegg, AE | 1 |
| Tentori, L | 1 |
| Vergati, M | 1 |
| Muzi, A | 1 |
| Levati, L | 1 |
| Ruffini, F | 1 |
| Forini, O | 1 |
| Vernole, P | 1 |
| Lacal, PM | 1 |
| Graziani, G | 1 |
| Park, JA | 1 |
| Joe, YA | 1 |
| Kim, TG | 1 |
| Hong, YK | 1 |
| Alonso, MM | 1 |
| Gomez-Manzano, C | 1 |
| Jiang, H | 1 |
| Bekele, NB | 1 |
| Piao, Y | 1 |
| Yung, WK | 1 |
| Alemany, R | 1 |
| Fueyo, J | 1 |
| Artemov, D | 1 |
| Bhujwalla, ZM | 1 |
| Maxwell, RJ | 1 |
| Griffiths, JR | 1 |
| Judson, IR | 1 |
| Leach, MO | 1 |
| Glickson, JD | 1 |
| Baer, JC | 1 |
| Freeman, AA | 1 |
| Newlands, ES | 2 |
| Watson, AJ | 1 |
| Rafferty, JA | 1 |
| Margison, GP | 1 |
| Stevens, MF | 2 |
| Wedge, SR | 1 |
| Wheelhouse, RT | 1 |
| Brock, C | 1 |
| Middlemas, DS | 1 |
| Stewart, CF | 1 |
| Kirstein, MN | 1 |
| Poquette, C | 1 |
| Friedman, HS | 1 |
| Brent, TP | 1 |
| Pulfer, S | 1 |
| Chu, J | 1 |
| Wilman, DE | 1 |
| Hickman, JA | 1 |
| Langdon, SP | 1 |
| Chubb, D | 1 |
| Vickers, L | 1 |
| Stone, R | 1 |
| Baig, G | 1 |
| Goddard, C | 1 |
| Gibson, NW | 1 |
| Slack, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063] | Phase 2 | 9 participants (Actual) | Interventional | 2013-04-25 | Completed | ||
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071] | Phase 1 | 9 participants (Actual) | Interventional | 2009-09-22 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (Paclitaxel, Carboplatin) | 3 |
| Arm 2 (Veliparib, Paclitaxel, Carboplatin) | 3 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
1 review available for temozolomide and Experimental Neoplasms
| Article | Year |
|---|---|
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Clinical Trial | 1997 |
42 other studies available for temozolomide and Experimental Neoplasms
| Article | Year |
|---|---|
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Crystallography, X-Ray; Dose-Response Relation | 2012 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair | 2021 |
Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Proliferation; Dose-Response Relationsh | 2022 |
Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Azabicyclo Compounds; Cell Death; Cell Proliferation; DN | 2022 |
Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biocompatible Materials; Cell Line, Tumor; Ce | 2021 |
SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers; DNA Damage; DNA Modification Meth | 2019 |
Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Mode | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2017 |
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Da | 2013 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazin | 2013 |
PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Cell Proliferation; Combined Moda | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbol | 2013 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality | 2013 |
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial | 2014 |
YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Topics: Adipokines; Animals; Antigens, Neoplasm; Biomarkers, Tumor; Cell Line, Tumor; Chitinase-3-Like Prote | 2014 |
Focused ultrasound with microbubbles increases temozolomide delivery in U87 transfected mice.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2015 |
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Blotting, Western; Carboplat | 2015 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line, Tumor; Dac | 2016 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; | 2009 |
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cystein | 2012 |
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimida | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherap | 2012 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Campto | 2002 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, An | 2003 |
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Synergism; | 2003 |
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarba | 2003 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Fema | 2005 |
Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Polyomavirus Transforming; Antineoplastic Agent | 2005 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; | 2007 |
Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer.
Topics: Animals; Antineoplastic Agents, Alkylating; Carbon Radioisotopes; Dacarbazine; Infusions, Intravenou | 1995 |
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Topics: Antineoplastic Agents; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Guanine; Human | 1993 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch | 2000 |
Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cyclohexanes; Dacarbazine; Dial | 2001 |
Prodrugs in cancer chemotherapy.
Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chem | 1986 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |